ABVC News and Press, ABVC BioPharma Inc. From 09/23/22

ABVC Biopharma ( NASDAQ: ABVC ) said on Friday that a Phase II Part 2  study testing its ADHD drug, ABV-1505, currently being conducted at five medical centers in Taiwan, had enrolled 30 subjects and eighteen of the enrolled participants had completed t...

Fremont, CA - ( NewMediaWire ) - September 22, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced enrollment progress in the Phase II Part 2 clinical study of t...

Fremont, CA - ( NewMediaWire ) - September 13, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a letter to shareholders. Dear Shareholders, I would like...

New Australia Site Confirmed to Participate in the Study  Fremont, CA - ( NewMediaWire ) - September 09, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today annou...

New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and op...

Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

ABVC BioPharma ( NASDAQ: ABVC ) on Thursday said it had got an approval from the ethics committee of a Thai hospital to conduct a phase 2 clinical study protocol for its vitreous substitute Vitargus. Shares of the micro-cap clinical-stage biopharmaceutical company opened 5.6...

ABVC BioPharma press release ( NASDAQ: ABVC ): Q2 GAAP EPS of -$0.06 beats by $0.07 . Revenue of $0.31M (+933.3% Y/Y) beats by $0.3M . For further details see: ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results f...

-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematol...